BioMarin fails to find buyer, pulls Roctavian gene therapy off market
BioMarin's previous CEO wanted to offer money-back guarantees to insurers for covering its hemophilia gene therapy Roctavian. Investors in the company may wish that such a promise on performance could...
View ArticleCan the ACCESS pilot crack a longstanding barrier for startups?
CMS is about to start paying for tech-supported care for Medicare enrollees. The pilot, called ACCESS, is a big deal. It opens up a huge new market of 30 million US seniors for digital health ...
View ArticleUCLA spinout raises $11M to test microbiome-based weight loss therapy
Bloom Science believes it has stumbled on a new approach to weight loss: a pill containing two strains of bacteria that alter the gut microbiome to replicate the effects of the ketogenic diet. The...
View ArticleIndustry groups lay legal groundwork against pricing demos
Pharma trade groups are laying the foundation for potential legal challenges to two CMS pricing demonstrations that they say are much broader than legally allowed and aren't actually intended to save...
View ArticleNovo Nordisk to slash Wegovy list price in half in 2027
Novo Nordisk said that starting next year, it will lower the list price of its popular GLP-1 products to $675 per month in a cost-cutting effort focused on patients with high insurance deductibles or...
View ArticleGSK to buy pulmonary hypertension biotech 35Pharma for $950M
GSK said on Wednesday that it is buying 35Pharma for $950 million, picking up the Canadian biotech's pulmonary hypertension drug program — and potentially dipping its toes into investigating weight...
View ArticleWho’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’...
For the fifth year running, Endpoints News will highlight the biotech leaders who are opening doors for people in the LGBTQ+ community. Nominations are now open for the 2026 edition of ...
View ArticlePolymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy
BreezeBio, a startup founded a decade ago to develop new delivery technologies for genetic medicines, has raised $60 million to start clinical trials of its first program, it announced Wednesday. The...
View ArticleNovo Nordisk teams with Langer-founded biotech for oral obesity drugs
For the third day in a row, Novo Nordisk has obesity news. The Danish behemoth will work with a relatively unknown biotech co-founded by MIT's Robert Langer to create oral biologics for obesity,...
View ArticleStates sue Kennedy over US childhood vaccine overhaul
HHS Secretary Robert F. Kennedy Jr. faces a second legal challenge related to the overhaul of the childhood vaccine schedule. Fifteen states claimed that HHS’ decision to downgrade recommendations for...
View ArticleAlkermes CEO Richard Pops to retire after 35-year tenure
Alkermes’ longtime CEO will step down this summer. Richard Pops plans to pass the torch to COO Blair Jackson, Alkermes announced Wednesday, wrapping up a career that spanned seven US presidencies....
View ArticleAccent axes a cancer study; Werewolf considers its options
Plus, news about Beam Therapeutics, Pfizer’s Braftovi regimen, Lonestar Medicines, the NOFLU vaccine consortium and Zura Bio: 🪓 Accent axes DHX9 inhibitor study: The biotech terminated the Phase 1 ...
View ArticleCharles River sells its CDMO and European discovery businesses
After searching for buyers for its "underperforming" assets, Charles River Laboratories has secured two deals. It will sell some of its European discovery services to the data and services company...
View ArticleMake way, Camzyos: Cytokinetics touts promising early launch for rival heart...
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against a Bristol Myers Squibb rival in a type of heart disease. Myqorzo launched in January and will ...
View ArticleGilead, Merck plan to debut new daily HIV pills
Gilead and Merck together are developing what could be the first weekly HIV pill, but they are also each making an individual push for new daily drugs. The two companies separately reported findings...
View ArticleSarepta CEO Doug Ingram to step down
Sarepta CEO Doug Ingram is stepping down from his role by the end of the year, ending a brash tenure in which he brought several Duchenne muscular dystrophy products to market and later presided over ...
View ArticleJapan's Asahi Kasei to buy German biotech Aicuris for $920M
The Japanese conglomerate Asahi Kasei is adding a biotech to its sprawling business portfolio, agreeing to acquire a longstanding privately held German company. Asahi Kasei announced Thursday it has...
View ArticleLilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
The second head-to-head Phase 3 trial in a week between dueling metabolic drugs from Eli Lilly and Novo Nordisk was reported Thursday. Once again, the data went Lilly’s way. The latest data came from a...
View ArticleOrbiMed jumps to number one on the top 100 list of biotech venture investors
This year’s list of the top 100 venture investors in the life sciences offered a few surprises, including OrbiMed’s vault into the number one slot on the list — jumping from its fourth-place finish for...
View ArticleSalma Health raises $80M for its clinics to treat brain health
A clinic that wants to use AI to move mental health treatment beyond trial-and-error prescribing to more precise care based on patients’ health data has raised $80 million in Series A funding,...
View ArticleNovartis to build another radioligand factory; Germany steps up probe into...
Novartis is building a new 46,000-square-foot factory in Denton, TX. Construction will start this year and is expected to be operational in 2028. The new facility is a part of its ...
View ArticleProtagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Protagonist Therapeutics will soon receive a significant amount of cash. Protagonist will opt out of its profit-sharing deal with Takeda on a rare disease drug, the biotech announced Wednesday,...
View ArticleAtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug
Plus, news about Boehringer Ingelheim, Sitryx Therapeutics, Argenx, Palvella Therapeutics, Vir Biotechnology, Larimar Therapeutics, Bristol Myers Squibb and SystImmune: 📉 AtaiBeckley releases Phase 2a...
View Article